APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human cytomegalovirus 65 kDa Phosphoprotein

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook and Growth Opportunities 2026

19 December 2025199 pages

Choose your research edition.

Industry ResearchHuman cytomegalovirus 65 kDa Phosphoprotein Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Human cytomegalovirus 65 kDa Phosphoprotein Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Human cytomegalovirus 65 kDa Phosphoprotein market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human cytomegalovirus 65 kDa Phosphoprotein market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human cytomegalovirus 65 kDa Phosphoprotein market include Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc and Vical Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human cytomegalovirus 65 kDa Phosphoprotein market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human cytomegalovirus 65 kDa Phosphoprotein and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human cytomegalovirus 65 kDa Phosphoprotein sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human cytomegalovirus 65 kDa Phosphoprotein market size, projected growth trends, production technologies, key applications, and end-use industries.

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Company

Astellas Pharma Inc

Hookipa Biotech AG

Immunomic Therapeutics Inc

Vakzine Projekt Management GmbH

Vaximm AG

VBI Vaccines Inc

Vical Inc

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Type

HB-101

ASP-0113

PepVax

CyMVectin

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Application

Hemotaological Tumor

Kidney Transplant Rejection

Brain Tumor

Liver Transplant Rejection

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human cytomegalovirus 65 kDa Phosphoprotein status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human cytomegalovirus 65 kDa Phosphoprotein market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human cytomegalovirus 65 kDa Phosphoprotein significant trends, drivers, influence factors in global and regions.

6. To analyze Human cytomegalovirus 65 kDa Phosphoprotein competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human cytomegalovirus 65 kDa Phosphoprotein market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human cytomegalovirus 65 kDa Phosphoprotein and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human cytomegalovirus 65 kDa Phosphoprotein.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human cytomegalovirus 65 kDa Phosphoprotein market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human cytomegalovirus 65 kDa Phosphoprotein industry.

Chapter 3: Detailed analysis of Human cytomegalovirus 65 kDa Phosphoprotein manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human cytomegalovirus 65 kDa Phosphoprotein in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human cytomegalovirus 65 kDa Phosphoprotein in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends Table 2. Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers Table 3. Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges Table 4. Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints Table 5. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Company (2021-2026) Table 7. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Company (2021-2026) Table 9. Global Human cytomegalovirus 65 kDa Phosphoprotein Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human cytomegalovirus 65 kDa Phosphoprotein Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human cytomegalovirus 65 kDa Phosphoprotein Key Company Manufacturing Base & Headquarters Table 12. Global Human cytomegalovirus 65 kDa Phosphoprotein Company, Product Type & Application Table 13. Global Human cytomegalovirus 65 kDa Phosphoprotein Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human cytomegalovirus 65 kDa Phosphoprotein by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of HB-101 Table 18. Significant Companies of ASP-0113 Table 19. Significant Companies of PepVax Table 20. Significant Companies of CyMVectin Table 21. Significant Companies of Others Table 22. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Type (2021-2026) Table 26. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Type (2027-2032) Table 27. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type (2021-2026) Table 31. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hemotaological Tumor Table 33. Significant Companies of Kidney Transplant Rejection Table 34. Significant Companies of Brain Tumor Table 35. Significant Companies of Liver Transplant Rejection Table 36. Significant Companies of Others Table 37. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Application (2021-2026) Table 41. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Application (2027-2032) Table 42. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application (2021-2026) Table 46. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application (2027-2032) Table 47. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2026) & (K Units) Table 49. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2021-2026) Table 50. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2027-2032) & (K Units) Table 51. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2027-2032) Table 52. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Region (2021-2026) Table 55. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Region (2027-2032) Table 57. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 62. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2026) Table 63. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032) & (K Units) Table 64. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2027-2032) Table 65. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Market Share by Country (2021-2026) Table 67. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Market Share by Country (2027-2032) Table 69. Astellas Pharma Inc Company Information Table 70. Astellas Pharma Inc Business Overview Table 71. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 73. Astellas Pharma Inc Recent Development Table 74. Hookipa Biotech AG Company Information Table 75. Hookipa Biotech AG Business Overview Table 76. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 78. Hookipa Biotech AG Recent Development Table 79. Immunomic Therapeutics Inc Company Information Table 80. Immunomic Therapeutics Inc Business Overview Table 81. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 83. Immunomic Therapeutics Inc Recent Development Table 84. Vakzine Projekt Management GmbH Company Information Table 85. Vakzine Projekt Management GmbH Business Overview Table 86. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 88. Vakzine Projekt Management GmbH Recent Development Table 89. Vaximm AG Company Information Table 90. Vaximm AG Business Overview Table 91. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 93. Vaximm AG Recent Development Table 94. VBI Vaccines Inc Company Information Table 95. VBI Vaccines Inc Business Overview Table 96. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 98. VBI Vaccines Inc Recent Development Table 99. Vical Inc Company Information Table 100. Vical Inc Business Overview Table 101. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 103. Vical Inc Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Human cytomegalovirus 65 kDa Phosphoprotein Distributors List Table 107. Human cytomegalovirus 65 kDa Phosphoprotein Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Human cytomegalovirus 65 kDa Phosphoprotein Product Image Figure 2. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (2021-2032) & (K Units) Figure 5. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human cytomegalovirus 65 kDa Phosphoprotein Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. HB-101 Image Figure 10. ASP-0113 Image Figure 11. PepVax Image Figure 12. CyMVectin Image Figure 13. Others Image Figure 14. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Type (2021-2032) Figure 17. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type (2021-2032) Figure 20. Hemotaological Tumor Image Figure 21. Kidney Transplant Rejection Image Figure 22. Brain Tumor Image Figure 23. Liver Transplant Rejection Image Figure 24. Others Image Figure 25. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Application (2021-2032) Figure 28. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application (2021-2032) Figure 31. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032) & (US$ Million) Figure 36. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032) & (US$ Million) Figure 42. South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Human cytomegalovirus 65 kDa Phosphoprotein Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • HB-101
  • ASP-0113
  • PepVax
  • CyMVectin
  • Others
Applications
  • Hemotaological Tumor
  • Kidney Transplant Rejection
  • Brain Tumor
  • Liver Transplant Rejection
  • Others
Companies covered
  • Astellas Pharma Inc
  • Hookipa Biotech AG
  • Immunomic Therapeutics Inc
  • Vakzine Projekt Management GmbH
  • Vaximm AG
  • VBI Vaccines Inc
  • Vical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032)
  4. 1.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume (2021-2032)
  5. 1.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human cytomegalovirus 65 kDa Phosphoprotein Market Dynamics
  1. 2.1 Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends
  2. 2.2 Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers
  3. 2.3 Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges
  4. 2.4 Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints
3 Human cytomegalovirus 65 kDa Phosphoprotein Market by Company
  1. 3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Company Revenue Ranking in 2025
  2. 3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Company (2021-2026)
  3. 3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Company (2021-2026)
  4. 3.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Average Price by Company (2021-2026)
  5. 3.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Company Ranking (2024-2026)
  6. 3.6 Global Human cytomegalovirus 65 kDa Phosphoprotein Company Manufacturing Base and Headquarters
  7. 3.7 Global Human cytomegalovirus 65 kDa Phosphoprotein Company Product Type and Application
  8. 3.8 Global Human cytomegalovirus 65 kDa Phosphoprotein Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human cytomegalovirus 65 kDa Phosphoprotein Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human cytomegalovirus 65 kDa Phosphoprotein Market by Type
  1. 4.1 Human cytomegalovirus 65 kDa Phosphoprotein Type Introduction
  2. 4.1.1 HB-101
  3. 4.1.2 ASP-0113
  4. 4.1.3 PepVax
  5. 4.1.4 CyMVectin
  6. 4.1.5 Others
  7. 4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Type
  8. 4.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Type
  12. 4.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Type (2021-2032)
  14. 4.3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type (2021-2032)
5 Human cytomegalovirus 65 kDa Phosphoprotein Market by Application
  1. 5.1 Human cytomegalovirus 65 kDa Phosphoprotein Application Introduction
  2. 5.1.1 Hemotaological Tumor
  3. 5.1.2 Kidney Transplant Rejection
  4. 5.1.3 Brain Tumor
  5. 5.1.4 Liver Transplant Rejection
  6. 5.1.5 Others
  7. 5.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Application
  8. 5.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Application
  12. 5.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Application (2021-2032)
  14. 5.3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application (2021-2032)
6 Human cytomegalovirus 65 kDa Phosphoprotein Regional Sales and Value Analysis
  1. 6.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2032)
  3. 6.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2021-2026
  4. 6.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2027-2032)
  5. 6.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Region (2027-2032)
  9. 6.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032)
  12. 6.6.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032)
  15. 6.7.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032)
  21. 6.9.2 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Country, 2025 VS 2032
7 Human cytomegalovirus 65 kDa Phosphoprotein Country-level Sales and Value Analysis
  1. 7.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2032)
  4. 7.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026)
  5. 7.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2027-2032)
  6. 7.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human cytomegalovirus 65 kDa Phosphoprotein Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma Inc
  2. 8.1.1 Astellas Pharma Inc Company Information
  3. 8.1.2 Astellas Pharma Inc Business Overview
  4. 8.1.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  6. 8.1.5 Astellas Pharma Inc Recent Developments
  7. 8.2 Hookipa Biotech AG
  8. 8.2.1 Hookipa Biotech AG Company Information
  9. 8.2.2 Hookipa Biotech AG Business Overview
  10. 8.2.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  12. 8.2.5 Hookipa Biotech AG Recent Developments
  13. 8.3 Immunomic Therapeutics Inc
  14. 8.3.1 Immunomic Therapeutics Inc Company Information
  15. 8.3.2 Immunomic Therapeutics Inc Business Overview
  16. 8.3.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  18. 8.3.5 Immunomic Therapeutics Inc Recent Developments
  19. 8.4 Vakzine Projekt Management GmbH
  20. 8.4.1 Vakzine Projekt Management GmbH Company Information
  21. 8.4.2 Vakzine Projekt Management GmbH Business Overview
  22. 8.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  24. 8.4.5 Vakzine Projekt Management GmbH Recent Developments
  25. 8.5 Vaximm AG
  26. 8.5.1 Vaximm AG Company Information
  27. 8.5.2 Vaximm AG Business Overview
  28. 8.5.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  30. 8.5.5 Vaximm AG Recent Developments
  31. 8.6 VBI Vaccines Inc
  32. 8.6.1 VBI Vaccines Inc Company Information
  33. 8.6.2 VBI Vaccines Inc Business Overview
  34. 8.6.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  36. 8.6.5 VBI Vaccines Inc Recent Developments
  37. 8.7 Vical Inc
  38. 8.7.1 Vical Inc Company Information
  39. 8.7.2 Vical Inc Business Overview
  40. 8.7.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  42. 8.7.5 Vical Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Analysis
  2. 9.1.1 Human cytomegalovirus 65 kDa Phosphoprotein Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human cytomegalovirus 65 kDa Phosphoprotein Sales Mode & Process
  6. 9.2 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors
  9. 9.2.3 Human cytomegalovirus 65 kDa Phosphoprotein Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst